Drugs & Targets Algen Biotechnologies, AstraZeneca form AI drug discovery partnership October 17, 2025Vol.51 No.38
Drugs & Targets FDA approves Libtayo for adjuvant treatment of cutaneous squamous cell carcinoma October 10, 2025Vol.51 No.37
Drugs & Targets FDA approves Zepzelca + Tecentriq combination as first-line maintenance therapy for ES-SCLC October 03, 2025Vol.51 No.36
Drugs & Targets FDA approves Inluriyo for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer October 03, 2025Vol.51 No.36
Drugs & Targets FDA grants Fast Track Designation to UB-VV111 in vivo CAR T-cell therapy October 03, 2025Vol.51 No.36
Drugs & Targets FDA approves Keytruda Qlex injection for subcutaneous use in 38 tumor indications September 26, 2025Vol.51 No.35By Jacquelyn Cobb
Drugs & Targets FDA grants priority review to HER2-directed therapy as first-line treatment of HER2-positive metastatic breast cancer September 26, 2025Vol.51 No.35
Drugs & Targets FDA approves gemcitabine intravesical system for non-muscle invasive bladder cancer September 19, 2025Vol.51 No.34
